Effects of Omeprazole on the Antiplatelet Activity of Clopidogrel

1. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, <i>et al</i>. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51: 172-209.

2. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, <i>et al</i>. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166-286.

3. Anderson JL, Adams CD, Antman EM, <i>et al</i>. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50: e1-157.

10.1161/01.CIR.0000013777.21160.07

10.1016/S0002-9149(01)01631-9

10.1161/01.CIR.0000072771.11429.83

10.1016/j.jacc.2004.09.067

10.1172/JCI200420986

9. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S-64S.

10.1001/jama.2009.261

11. Price MJ, Endemann S, Gollapudi RR, <i>et al</i>. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000.

10.1016/j.jacc.2007.01.003

10.1016/j.jacc.2005.07.056

10.1161/01.CIR.0000130846.46168.03

10.1111/j.1538-7836.2005.01751.x

16. Wang ZJ, Zhou YJ, Liu YY, <i>et al</i>. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Thromb Res 2009; 124: 46-51.

17. Kim JY, Yoon J. Aspirin and Clopidogrel Resistance in Drug Eluting Stent Era. Korean Circ J 2007; 37: 135-47. (Review)

18. De Miguel A, Ibanez B, Badim&oacute;n JJ. Clinical implications of clopidogrel resistance. Thromb Haemost 2008; 100: 196-203. (Review)

10.1016/j.thromres.2006.08.012

10.1038/sj.clpt.6100139

10.1016/j.jacc.2007.06.064

22. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157: 148.e1-5.